Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

SOF/VEL/VOX safe, effective for rescue hepatitis C treatment

02 Oct 2019

The combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is safe and effective as rescue therapy for hepatitis C patients in whom prior direct-acting antivirals (DAAs) had failed, a new study has found.

Researchers conducted a prospective, multicentre study on 137 patients (median age, 56 years; 75 percent male), who had experienced DAA failure. All participants received 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir contained in a fixed-dose tablet. The primary endpoint was sustained virological response after 12 weeks (SVR 12).

Excluding two patients who were lost to follow-up, 128 of the remaining 135 participants achieved SVR 12. The resulting rate was 95 percent. This was higher in those without cirrhosis, as compared to their cirrhotic counterparts (98 percent vs 89 percent; p=0.05).

SVR 12 rates did not vary according to Child-Turcotte-Pugh scores (p=0.19), the presence of hepatocellular carcinoma (p=0.07), coinfection with HIV (p=0.72) or a history of liver transplant (p=0.66).

On the other hand, 131 participants showed evidence of treatment-related adverse events. Of these, only 25 had mild adverse episodes, most common of which were headaches (36 percent) and asthenia (32 percent). None had to discontinue treatment due to side effects

One patient developed multicentric hepatocellular carcinoma and, after 8 weeks of treatment, had jaundice. The situation worsened quickly and the patient ultimately died before achieving SVR 12.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.